Physician profile
Robert E Kuhn
NPI 1104818681
$6,360.74
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $543 · 2021: $1,598 · 2022: $1,482 · 2023: $1,096 · 2024: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $865.60 | 2021-2024 | |
| Novo Nordisk INC | $704.63 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $452.03 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $432.51 | 2019-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $339.85 | 2019-2024 | Emgality, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.87 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $301.77 | 2019-2023 | Shingrix, Arexvy |
| Dexcom, INC. | $275.20 | 2021-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $254.15 | 2019-2023 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $253.83 | 2020-2024 | Vaxelis, Proquad, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $213.35 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $210.29 | 2019-2022 | |
| Tris Pharma INC | $189.70 | 2021 | |
| Corium, LLC | $162.68 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $142.40 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kuhn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.